Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Nervous system drugs >  Antidepressants, Antimanics drugs >  DOXEPIN

DOXEPIN

Basic information Safety Supplier Related

DOXEPIN Basic information

Product Name:
DOXEPIN
Synonyms:
  • (3Z)-3-Dibenzo[b,E]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
  • 11-(3-(dimethylamino)propylidene)-6h-dibenz(b,e)0xepine
  • 11-(3-dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
  • 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
  • 3-dibenz(b,e)oxepin-11(6h)-ylidene-n,n-dimethyl-1-propanamin
  • Quitaxon
  • 1-Propanamine, 3-dibenzb,eoxepin-11(6H)-ylidene-N,N-dimethyl-
  • 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin
CAS:
1668-19-5
MF:
C19H21NO
MW:
279.38
EINECS:
214-966-8
Product Categories:
  • Heterocyclic Compounds
  • Neurochemicals
Mol File:
1668-19-5.mol
More
Less

DOXEPIN Chemical Properties

Melting point:
187-189°C
Boiling point:
bp0.03 154-157°; bp0.2 260-270°
Density 
1.0594 (rough estimate)
refractive index 
1.5000 (estimate)
storage temp. 
Sealed in dry,2-8°C
pka
9.40±0.28(Predicted)
Water Solubility 
31.57mg/L(25 ºC)
EPA Substance Registry System
Doxepin (1668-19-5)
More
Less

Safety Information

Hazard Codes 
T
Risk Statements 
25
Safety Statements 
36/37/39-45
Hazardous Substances Data
1668-19-5(Hazardous Substances Data)
Toxicity
LD50 in mice, rats (mg/kg): 26, 16 i.v.; 79, 182 i.p.; 135, 147 orally (Ribbentrop, Schaumann)
More
Less

DOXEPIN Usage And Synthesis

Originator

Sinequan,Pfizer,US,1969

Uses

Used clinically to treat anxiety and depression. Antidepressant

Definition

ChEBI: A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.

Manufacturing Process

(A) Preparation of 3-bromopropyltriphenylphosphonium bromide: Triphenylphosphine, 1.0 kg, and 770 grams of 1,3-dibromopropane are dissolved in 2.0 liters of xylene and the solution is stirred under a nitrogen atmosphere at 130°C. After 20 hours the mixture is cooled, and the crystalline product, which precipitates, is collected and washed with 20 liters of benzene. After drying in vacuo the product weighs 1,578 grams, MP 229°-230°C;titration for bromide ion: Found, 17.1%; calculated, 17.2%.
(B) Preparation of 3-dimethylaminopropyltriphenylphosphonium bromide hydrobromide: A solution of 595 grams of anhydrous dimethylamine and 1,358 grams of 3-bromopropyl-triphenylphosphonium bromide in 4 liters of ethanol is warmed to 70°C until solution is complete and the solution then is allowed to stand at room temperature for 20 hours. Volatile components are removed by distillation in a vacuum and the residue is suspended in 2.0 liters of ethanol and is redistilled to remove excess amine. The residue is dissolved in 3.0 liters of warm ethanol and gaseous hydrogen bromide is passed into the solution until the mixture is acidic. After filtration the solution is concentrated to a volume of 3.0 liters, is cooled, whereupon the product precipitates, and the precipitate is collected; it weighs 1,265 grams, MP 274- 281°C. Recrystallization from ethanol raises the MP to 280.5°-282.5°C. Bromide ion titration: Found, 31.2%; calculated 31.3%.
(C) Preparation of doxepin: 1,530 grams of the product from step (B) is suspended in 4.5 liters dry tetrahydrofuran and 6.0 mols of butyl lithium in heptane is added during 1 hour. After an additional 30 minutes, 483 grams of 6,11-dihydrodibenz-(b,e)oxepin-11-one, prepared as described in Belgian Patent 641,498, is added to the deep red solution and the reaction was maintained at reflux for 10 hours. Water, 500 ml, is added at room temperature and the solvent is removed in vacuo. The crude residue is treated with 10% hydrochloric acid until acidic (pH 2) and then 1.5 liters benzene is added. After stirring, the mixture separates into 3 phases (an insoluble hydrochloride salt product phase, an aqueous phase and an organic phase).
The benzene layer is removed by decantation and the remaining mixture is rendered basic with 10% sodium hydroxide solution and is extracted with three 1,500 ml portions of benzene. The benzene extracts are washed, then dried with anhydrous sodium sulfate and concentrated in a vacuum leaving a residue of 1,530 grams, gas and thin layer chromatography analysis show this to be a cis/trans mixture (approx. 4:l) of 11-dimethylaminopropylidene-6,11- dihydrodibenz-(b,e)oxepin (90% yield). This mixture has substantially more activity pharmacologically than the cis/trans mixture obtained by the Grignard route disclosed in the Belgian Patent 641,498. This base is then converted to the hydrochloride with HCl.

brand name

Apo-doxepin;Co dox;Deptran;Doksapan;Dolat;Doxal;Doxedyn;Doxepin hcl;Gilex;Novo-doxepin;Novoxapin;Sinequan;Sinquan concentrate;Sinquane;Tolllluan;Triadapin;Zonalon.

Therapeutic Function

Tranquilizer

World Health Organization (WHO)

Doxepin, a tricyclic antidepressant was introduced in 1964 for the management of endogenous depression. Much of the adverse effects are caused by its antimuscarinic actions. These include dry mouth, cardiac arrhythmias, central nervous system disturbances, blood disorders and risk of suicide. The risk of suicide and dangers related to overdosage led the Norwegian Medicines Control Authority to put the higher strength formulation under prescribing restriction in 1992. The risk of death following overdosage is apparently higher for products containing tricyclic compounds as compared with nontricyclic products.

Biological Activity

Highly potent H 1 histamine receptor antagonist (K d = 310 pM) and tricyclic antidepressant. Also binds to the H 4 histamine receptor (pK i = 6.79).

Contact allergens

This benzoxepin tricylcic drug has antidepressant, anticholinergic, antiitching, and antihistamine properties. After oral use, it has been developed as a topical antiitching agent. Allergic contact dermatitis is not infrequent.

DOXEPIN Preparation Products And Raw materials

Raw materials

DOXEPINSupplier

3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
EMMX Biotechnology LLC
Tel
888-539-0666
Email
info@emmx.com